13 citations
,
April 2001 in “Journal of The American Academy of Dermatology” Using a vibrating device during injections can help reduce pain.
2 citations
,
November 2025 in “Pharmacology Research & Perspectives” This study analyzed post-marketing data from the U.S. FDA Adverse Event Reporting System and identified both known and new safety concerns for Avacopan, an anti-neutrophil cytoplasmic antibodies-associated vasculitis treatment, emphasizing the need for monitoring during early treatment stages.
1 citations
,
October 2025 in “Frontiers in Immunology” In this study, researchers analyzed adverse events linked to avacopan using FDA data, finding no high-priority safety concerns but identifying five potential new adverse events, including alopecia, primarily among American patients, and noting a higher risk of liver dysfunction in Japanese patients.
26 citations
,
January 1992 in “Cancer investigation” This study found that N-acetylcysteine effectively prevented cyclophosphamide-induced alopecia in rats, and ImuVert plus N-acetylcysteine prevented alopecia from a cyclophosphamide-cytarabine combination.
2 citations
,
September 2022 in “Advances in Environmental Biology” This study found that ethanolic extracts of Avicennia marina leaves showed potential antibacterial activity against Vancomycin-Resistant Enterococcus faecium but were less effective than standard antibiotics.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” In this study, researchers using network pharmacology and molecular docking methods found that compounds from Avicennia Marina could inhibit hepatitis C virus infection by targeting key proteins such as AKT1 and TNF-α, showing potential for anti-HCV treatments.
This study found that Avicennia marina extract and its active compound avicequinone C inhibit enzymes and receptors related to androgenic alopecia, potentially supporting hair growth in cultured dermal papilla cells.
This compilation details various potential side effects and interactions of vitamin A, but it reports no new research findings.
August 2025 in “International Journal of Molecular Sciences” This study found that arginine vasotocin is evolutionarily conserved across diverse taxa and may play roles in neuroendocrine, immune, and stress signaling, with potential antimicrobial applications.
November 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.
19 citations
,
May 2014 in “Molecules” This study found that the methanolic heartwood extract of Avicennia marina significantly inhibits 5α-reductase type 1, reducing 5α-DHT production by 52% in a cell-based assay with human hair dermal papilla cells.
8 citations
,
May 2019 in “Journal of dermatological treatment” This study found that vismodegib was effective in treating basal cell carcinoma, achieving complete remission in some patients; however, significant side effects often required careful management to prevent therapy suspension, which can lead to resistance.
June 2026 in “British Journal of Dermatology” This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.
This study found that Avicennia marina extract significantly increased hair growth in androgenic alopecia patients, suggesting its potential effectiveness by inhibiting 5 alpha-reductase and regulating relevant growth factors.
May 2020 in “The journal of investigative dermatology/Journal of investigative dermatology” This study reported that specific inhibition of the classical complement pathway with BIVV009 prevented C3 deposition along the dermal-epidermal junction in bullous pemphigoid, reflecting its potential efficacy.
15 citations
,
January 2024 in “The AAPS Journal” This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.
16 citations
,
April 2000 in “Journal of Investigative Dermatology” The study reports that the AVET system showed higher efficiency in transfecting cultured human keratinocytes compared to SuperFect and PrimeFector, with AVET reaching levels of enzyme activity similar to normal cells in keratinocytes from lamellar ichthyosis patients.
4 citations
,
August 2023 in “Biomedicine & Pharmacotherapy” This study found that in noise-exposed FVB/NJ mice and cell models, ivacaftor reduced oxidative stress and hearing damage by maintaining CFTR function and increasing Nrf2 expression, suggesting its potential for treating noise-induced hearing loss.
In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.
28 citations
,
September 2016 in “Future oncology” In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” In this case report, a nine-year-old child with vitiligo and alopecia areata was successfully treated with upadacitinib and UVB, resulting in a significant reduction in the affected areas, suggesting a promising treatment approach for similar pediatric cases.
August 2026 in “JAMA Dermatology” This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.
10 citations
,
May 2011 in “American Journal of Hematology” This study found that vinblastine treatment rapidly increased platelet counts in childhood refractory immune thrombocytopenia, providing effective control of bleeding symptoms, although side effects like neuropathic pain were common and resolved with dose adjustments.
May 2026 in “International Journal of Applied Pharmaceutics” This study developed a stable nanoemulsion of Avicennia marina heartwood extract showing promising anti-dandruff activity against Pityrosporum ovale and favorable physicochemical properties, which supports its potential use in topical formulations.
2 citations
,
October 2025 in “Antimicrobial Agents and Chemotherapy” This study found that cepharanthine may be a promising treatment for enterovirus infections, as it offered full protection to mice against lethal EV71 challenges and reduced viral titers and pathology.
2 citations
,
July 2025 in “Scientific Reports” This study identified a novel Acinetobacter species, strain A1-4-2, with exceptional biodegradation abilities and low antibiotic resistance, found in diverse environments and potentially useful for ecological restoration by degrading organic pollutants.
1 citations
,
July 2024 in “Journal of Investigative Dermatology” VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
1 citations
,
February 2012 This abstract provides an overview of various topics related to pharmaceutical and therapeutic interventions, including acyclovir and photodynamic therapy for alopecia, but does not report new research findings.
3 citations
,
May 2025 in “Frontiers in Pharmacology” This study identified known and potential novel adverse events, such as squamous cell carcinoma and dehydration, for vismodegib, underlining the importance of monitoring especially in the first two months of treatment.